We did not examine whether or not these health behaviors had a protective effect on cognition in the context of disease (i.e., Alzheimer’s disease biomarkers including beta-amyloid plaques, phosphorylated tau, and neurodegeneration [38]), which will be an important area of future study in the WRAP cohort. The gene discussed is MAPT; the disease is Alzheimer disease.